Propensity to excessive proinflammatory response in chronic Lyme borreliosis

APMIS

Volumn 115, Issue 2, 2007, Pages 134-141

  Kisand, Kai E ^a,b   Prükk, Tiina ^b   Kisand, Kalle V ^a   Lüüs, Siiri Merike ^c   Kalbe, Irja ^c   Uibo, Raivo ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c TARTU UNIVERSITY HOSPITAL   (Estonia)

Author keywords

IL 10; Lyme borreliosis; Monocyte; Regulatory T cell; TNF

Indexed keywords

BACTERIAL ANTIGEN; CEFTRIAXONE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXYCYCLINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTHROPATHY; ARTICLE; BORRELIA BURGDORFERI; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LYME DISEASE; MALE; MONOCYTE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEX RATIO; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYME DISEASE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED;

EID: 33846798515     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.apm_538.x     Document Type: Article

References (32)

1. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a tickborne spirochetosis? Science 1982;216:1317-9.
2. Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti JC, Assous M, et al. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol 1992;42:378-83.
3. Kisand KE, Utt M, Kisand KV, Prukk T, Uibo R. Serological description of Estonian patients with Lyme disease, a comparison with control sera from endemic and non-endemic areas. Int J Med Microbiol 2004;293 (Suppl):S174-S8.
4. Ekerfelt C, Forsberg P, Svenvik M, Roberg M, Bergstrom S, Ernerudh J. Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection. Clin Exp Immunol 1999;115:498-502.
5. Singh SK, Girschick HJ. Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi. Lancet Infect Dis 2004;4:575-83.
6. Sjowall J, Carlsson A, Vaarala O, Bergstrom S, Ernerudh J, Forsberg P, et al. Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol 2005;141:89-98.
7. Sellati TJ, Bouis DA, Caimano MJ, Feulner JA, Ayers C, Lien E, et al. Activation of human monocytic cells by Borrelia burgdorferi and Treponema pallidum is facilitated by CD14 and correlates with surface exposure of spirochetal lipoproteins. J Immunol 1999;163:2049-56.
8. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002;8:878-84.
9. Giambartolomei GH, Dennis VA, Lasater BL, Philipp MT. Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14. Infect Immun 1999;67:140-7.
10. Diterich I, Harter L, Hassler D, Wendel A, Hartung T. Modulation of cytokine release in ex vivo-stimulated blood from borreliosis patients. Infect Immun 2001;69:687-94.
11. Glickstein L, Moore B, Bledsoe T, Damle N, Sikand V, Steere AC. Inflammatory cytokine production predominates in early Lyme disease in patients with erythema migrans. Infect Immun 2003;71:6051-3.
12. Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kiely TG, Dardick KR, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003;171:2660-70.
13. Widhe M, Grusell M, Ekerfelt C, Vrethem M, Forsberg P, Ernerudh J. Cytokines in Lyme borreliosis: lack of early tumour necrosis factor-alpha and transforming growth factor-beta1 responses are associated with chronic neuroborreliosis. Immunology 2002;107:46-55.
14. Giambartolomei GH, Dennis VA, Lasater BL, Murthy PK, Philipp MT. Autocrine and exocrine regulation of interleukin-10 production in THP-1 cells stimulated with Borrelia burgdorferi lipoproteins. Infect Immun 2002;70:1881-8.
15. Brown JP, Zachary JF, Teuscher C, Weis JJ, Wooten RM. Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense. Infect Immun 1999;67:5142-50.
16. Schroder NW, Diterich I, Zinke A, Eckert J, Draing C, Baehr VV, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005;175:2534-40.
17. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6:353-60.
18. Nardelli DT, Burchill MA, England DM, Torrealba J, Callister SM, Schell RF. Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody. Clin Diagn Lab Immunol 2004;11:1075-84.
19. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
21. Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005;66:13-20.
22. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol 2006;24:209-26.
23. Zajkowska JM, Hermanowska-Szpakowicz T. Subpopulations of the peripheral lymphocytes in the early clinical forms of Lyme disease. Med Sci Monit 2000;6:278-84.
24. De Jong R, Brouwer M, Hooibrink B, Van der Pouw-Kraan T, Miedema F, Van Lier RA. The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993-9.
25. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257-63.
26. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56.
27. Nilsson I, von Rosen IA. Serum antibodies against Borrelia afzelii, Borrelia burgdorferi sensu stricto and the 41-kiloDalton flagellin in patients from a Lyme borreliosis endemic area: analysis by EIA and immunoblot. APMIS 1996;104:907-14.
28. Wilske B. Diagnosis of lyme borreliosis in europe. Vector Borne Zoonotic Dis 2003;3:215-27.
29. Skinner NA, MacIsaac CM, Hamilton JA, Visvanathan K. Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens. Clin Exp Immunol 2005;141:270-8.
30. Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 2005;174:5907-14.
31. Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, Forsberg P, et al. Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 2004;189:1881-91.
32. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338-44.